

NeoGenomics, Definiens to develop novel assays, 6/17

June 2017—NeoGenomics and Definiens have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing. Under the agreement, Definiens will provide automated quantitative biomarker solutions to support NeoGenomics' immunohistochemistry services for its pharma services customers and clinical clients, helping to improve pathology interpretation, standardize the readout (analysis/scoring), and identify the signature for optimal biomarker cut-point threshold.

[NeoGenomics](#), 866-776-5907

[Definiens](#), 617-949-4000